Transcriptional Activation of the Factor VIII Gene in Liver Cell Lines by Interleukin-6

David Stirling; Wendy A. Hannant; Christopher A. Ludlam

doi:10.1055/s-0037-1614223

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1998; 79(01): 74-78
DOI: 10.1055/s-0037-1614223

Review Article

Schattauer GmbH

Transcriptional Activation of the Factor VIII Gene in Liver Cell Lines by Interleukin-6

Authors

David Stirling

From the Department of Haematology, Royal Infirmary of Edinburgh NHS Trust, Edinburgh, UK
Wendy A. Hannant

From the Department of Haematology, Royal Infirmary of Edinburgh NHS Trust, Edinburgh, UK
Christopher A. Ludlam

From the Department of Haematology, Royal Infirmary of Edinburgh NHS Trust, Edinburgh, UK

Abstract

Summary

Circulating factor VIII (fVIII) levels increase during inflammation suggesting that fVIII synthesis or secretion is stimulated during acute inflammation. To examine the mechanisms underlying this increase in circulating factor VIII, we have developed a sensitive and reliable semi-quantitative assay for fVIII mRNA utilising competitive reverse transcriptase-polymerase chain reaction (RT-PCR, and used this to study two human liver cell lines, Hep-G2 and Chang Liver cells. These cells were cultured under basal conditions or following treatment with interleukin-1, -2 and 6 (IL-1, -2, and -6). Following 18h culture with IL-6 (maximum concentration 40U/ml), these levels had risen 6 and 9 fold respectively, with no concomitant rise in control RNA levels. The dose responses for both cell types were similar, with an ED₅₀ of 11 U/ml. The time course of this response was also similar in both cell lines with the increase in fVIII mRNA first reaching significance by 3 h, and reaching maximum levels by 12 h. IL-1 and IL-2 had no effect at any of the doses studied. This study provides the first evidence for regulated expression of fVIII in human cell lines, and suggests that increased plasma fVIII levels during the acute phase response may be due to increased expression of fVIII mRNA.

Volltext

Referenzen

References
1 Hawkey CJ, Stirling Y, Chakrabarti R, Brozovic M, Cox AG, Meade TW. Haemostatic changes following surgery. Thromb Res 1983; 32: 223-7.
2 Lombardi R, Mannucci PM, Seghatchian MJ, Garcia VV, Coppola R. Alterations of factor VIII von Willebrand factor in clinical conditions associated with an increase in its plasma concentration. Br J Haematol 1981; 49: 61-8.
3 Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction results of the ECAT angina pectoris study group. Thromb Haemost 1995; 73: 561-7.
4 Tuddenham ED, Cooper DN. Factor VIII and haemophilia. In: Tuddenham ED, Cooper DN. eds The molecular genetics of haemostasis and its inherited disorders. Oxford University Press; Oxford, UK: 1994. pp 19-77.
5 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
6 Staros JV, Wright RW, Swingle DM. Enhancement of n-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. Anal Biochem 1986; 156: 220-2.
7 Montandon AJ, Green PM, Giannelli F, Bentley DR. Direct detection of point mutations by mismatch analysis: application to haemophilia B. Nucleic Acids Res 1989; 17: 3347-58.
8 Maniatis T, Frisch EF, Sambrook J. Extraction purification and analysis of mRNA from Eukaryotic cells. In: Maniatis T, Fritsch EF, Sambrook J. eds. Molecular biology; a laboratory manual. New York: Cold Spring Harbour; 1982. p 188.
9 Toole JJ, Knopf JL, Wozney JM, Sultman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemakor C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-7.
10 Rall LB, Bell GI, Caput D, Truett MA, Masiarz FR, Majarian RC, Valenzuela P, Anderson HD, Din N, Hansen B. Factor VIII:C synthesis in the kidney (letter). Lancet 1985; 1: 44.
11 Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
12 Wion KL, Kelly D, Summerfield JA, Tuddenham EG, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-9.
13 Gilliland G, Perrin S, Bunn HF. Competitive PCR for quantitation of mRNA. In: PCR Protocols; A guide to methods and applications. Innes MA, Gelfand DH, Sninsky JJ, White TJ. eds. Academic Press; San Diego, CA: 1996. pp 60-4.
14 Baumann H. Hepatic acute phase reaction in vivo and in vitro. Cell Dev Biol 1989; 25: 115-26.
15 Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 1993; 13: 276-88.
16 Hocke GM, Barry D, Fey GH. Synergistic action of interleukin-6 and glucocorticoids is mediated by the interleukin-6 response element of the rat alpha2 macroglobulin gene. Mol Cell Biol 1992; 12: 2282-94.
17 Figueiredo MS, Brownlee GG. cis-Acting elements and transcription factors involved in the promoter activity of the human factor VIII gene. J Biol Chem 1995; 270: 11828-38.
18 Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII ABO blood group and the incidence of ischaemic heart disease. B J Haematol 1994; 88: 601-7.
19 Rizza CR, Spooner RJ. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the direc tors of haemophilia centres in the United Kingdom. Br Med J [Clin Res] 1983; 286: 929-33.
20 Johnson RE, Lawrence DN, Evatt BL, Bregman DJ, Zyla LD, Curran JW, Allerdot LM, Eyster ME, Brownstein AP, Carman CJ. Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States. Am J Epidemiol 1985; 121: 797-810.
21 Rosendaal FR, Varekamp I, Smit C, Bröcker-Vriends AH, van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TP, Briët E. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71: 71-6.
22 Hirsh J, Hull R, Raskob GE. Epidemiology and pathogenesis of venous thromboembolism. J Am Coll Cardiol 1986; 8: 104B-13B.
23 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a pre viously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 1004-8.
24 Koster T, Rosendaal FR, De Ronde, Briët E, Vanenbrooke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
25 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
26 Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
27 Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53: 387-94.
28 Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delurat E, Tuddenham EGD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-7.
29 Ercolani L, Florence B, Denaro M, Alexander M. Isolation and complete sequence of a functional human glyceraldehyde- 3-phosphate dehydrogenase gene. Journal of Biological Chemistry 1988; 263: 15335-41.